{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:33:08Z","timestamp":1780680788951,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inflammatory myositis, such as dermatomyositis, is sometimes complicated by cancer and is recognized as cancer-associated myositis. Although some autoimmune antibodies are considered to be involved in the development of myositis in cancer patients, the precise mechanism has not been clarified. The findings of the present case shed light on the mechanism by which anti-transcriptional intermediary factor 1 (TIF1)-\u03b3 Ab was produced and the pathogenesis of cancer-associated myositis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We describe a case of dermatomyositis that developed in a 67-year-old man who had been diagnosed with small cell lung cancer of clinical T4N3M0 stage IIIB\/limited disease during treatment. He received systemic chemotherapy and radiation therapy, and dermatomyositis developed along with a significant decrease in tumor size. TIF1-\u03b3 Ab, which is one of the myositis-specific antibodies, was found to be seroconverted. In addition, immunohistochemical analysis showed that cancer cells were positive for the TIF1-\u03b3 antigen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings of the present case suggest that transcriptional intermediary factor 1-\u03b3, which is released from tumor cells, induces the production of TIF1-\u03b3 Ab, leading to the development of dermatomyositis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-01974-4","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:03:15Z","timestamp":1652346195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of dermatomyositis after anti-transcriptional intermediary factor 1-\u03b3 antibody seroconversion during treatment for small cell lung cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Yuki","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Nikaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Rikimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Minemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syoki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"1974_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513\u201322. https:\/\/doi.org\/10.1002\/art.33403.","journal-title":"Arthritis Rheum"},{"key":"1974_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2340\/00015555-3091","volume":"99","author":"M Best","year":"2019","unstructured":"Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D. Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99:256\u201362. https:\/\/doi.org\/10.2340\/00015555-3091.","journal-title":"Acta Derm Venereol"},{"key":"1974_CR3","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O\u2019Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682\u20139. https:\/\/doi.org\/10.1002\/art.22164.","journal-title":"Arthritis Rheum"},{"key":"1974_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/sj.onc.1202655","volume":"18","author":"L Venturini","year":"1999","unstructured":"Venturini L, You J, Standler M, Galien R, Lallemand V, Koken MH, et al. TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene. 1999;18:1209\u201317. https:\/\/doi.org\/10.1038\/sj.onc.1202655.","journal-title":"Oncogene"},{"key":"1974_CR5","doi-asserted-by":"publisher","first-page":"e33761","DOI":"10.1371\/journal.pone.0033761","volume":"7","author":"G Andrieux","year":"2012","unstructured":"Andrieux G, Fattet L, Le Borgne M, Rimokh R, Th\u00e9ret N. Dynamic regulation of Tgf-B signaling by TIF1\u03b3: a computational approach. PLoS ONE. 2012;7:e33761. https:\/\/doi.org\/10.1371\/journal.pone.0033761.","journal-title":"PLoS ONE"},{"key":"1974_CR6","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1038\/ncomms7156","volume":"6","author":"J Xue","year":"2015","unstructured":"Xue J, Chen Y, Wu Y, Wang Z, Zhou A, Zhang S, et al. Tumour suppressor TRIM33 targets nuclear \u03b2-catenin degradation. Nat Commun. 2015;6:6156. https:\/\/doi.org\/10.1038\/ncomms7156.","journal-title":"Nat Commun"},{"key":"1974_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/onc.2015.141","volume":"35","author":"L Wang","year":"2016","unstructured":"Wang L, Yang H, Lei Z, Zhao J, Chen P, Li C, et al. Repression of TIF1\u03b3 by SOX2 promotes TGF-\u03b2-induced epithelial-mesenchymal transition in non-small-cell lung cancer. Oncogene. 2016;35:867\u201377. https:\/\/doi.org\/10.1038\/onc.2015.141.","journal-title":"Oncogene"},{"key":"1974_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726\u201333. https:\/\/doi.org\/10.1093\/rheumatology\/keq153.","journal-title":"Rheumatology (Oxford)"},{"key":"1974_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/key357","volume":"58","author":"A Oldroyd","year":"2019","unstructured":"Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019;58:650\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/key357.","journal-title":"Rheumatology (Oxford)"},{"key":"1974_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2169\/internalmedicine.1007-18","volume":"58","author":"T Aritomi","year":"2019","unstructured":"Aritomi T, Kido T, Nakano K, Satoh Y, Noguchi S, Jotatsu T, et al. Small cell lung cancer patient with anti-transcriptional intermediary factor 1\u03b3 antibody who developed dermatomyositis after successful chemoradiotherapy. Intern Med. 2019;58:427\u201331. https:\/\/doi.org\/10.2169\/internalmedicine.1007-18.","journal-title":"Intern Med"},{"key":"1974_CR11","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2169\/internalmedicine.4702-20","volume":"59","author":"Y Nakanishi","year":"2020","unstructured":"Nakanishi Y, Yamaguchi K, Yoshida Y, Sakamoto S, Horimasu Y, Masuda T, et al. Coexisting TIF1\u03b3-positive primary pulmonary lymphoepithelioma-like carcinoma and anti-TIF1\u03b3 antibody-positive dermatomyositis. Intern Med. 2020;59:2553\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.4702-20.","journal-title":"Intern Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:04:08Z","timestamp":1652346248000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1974"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01974-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s wife to publish this case report and images because the patient had passed away.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}